HIV i-Base

Poppers linked to permanent and serious vision loss

This is a pre-press article for the November/December edition of HTB. Simon Collins, HIV i-Base Serious vision loss linked to recreational use of poppers has been reported as a case study in this weeks issue of the Lancet. The vision …

Q&A on PrEP in the UK and changes to the HIV PROUD study

The following Q&A was produced by i-Base about PrEP in the UK including recent changes to the PROUD study. Participants in the study will be contacted shortly by the study team. People enrolled in PROUD can also contact their clinic …

September/October HTB now online

Featured

Reports from the 54th ICAAC and IAS 2014 conferences, newly approved drugs for HIV and hepatitis C, new UK guidelines for pregnancy and PEP, plus a potential new approach for PML…

July/August HTB now online

Ten reports from AIDS 2014, coverage from paediatric and INTEREST workshops, London guidelines, dolutegravir access in the UK, plus lots more…

IAS 2014: news from Melbourne

Short reports and links to news at the 20th World AIDS Conference: cure research, PrEP (do you swallow?), pipeline report, HIV and children, HIV-related complications, activists protest Gilead’s price for sofosbuvir and global TasP…

Latvian guides now include HIV and pregnancy

A new Latvian translation of the i-Base guide to HIV, Pregnancy and Women’s Health is now online. This is the fourth i-Base guide to be translated into Latvian, in collaboration with Association HIV.LV and the EATG COPE project. HIV, pregnancy …

May/June HTB now online

Reports from EASL, BHIVA and CROI: new hepatitis C drugs, including pricing and UK access; ARVs in pregnancy; early use in babies; tenofovir in Zambia; US guidelines for treatment and PrEP; all this and more…

March/April HTB now online

CROI 2014: 15 reports: ARVs, prevention, MTCT, paediatrics, TB and cure plus reviews of important basic science and cure research developments…

CROI 2014: early reports

First reports from CROI 2014: no linked HIV transmissions when viral load is suppressed; 3-monthly PrEP injections, PI/r monotherapy, ACTG 5257, NEAT001, paediatric ARV pipeline, low dose efavirenz and more…

Post navigation